| アブストラクト | There has been growing concern in worsening survival and renal outcomes following vancomycin-associated nephrotoxicity (VAN) onset, but the factors associated with these phenomena remain unclear. To examine these factors, we performed a retrospective study combining the analysis of two real-world databases. Initially, the FDA Adverse Event Reporting System (FAERS) was used to evaluate the relationship between VAN and mortality using odds ratios (ORs) and 95% confidence intervals (CIs). Next, electronic medical records (EMRs) were examined in a more robust cohort for evaluation of the association between renal outcomes and worsening survival using Cox proportional hazards regression models. FAERS analysis revealed a significant correlation between VAN occurrence and increased mortality (OR: 1.30; 95% CI: 1.17-1.46). EMR analysis showed that non-recovery of VAN was associated with increased hospital mortality (hazard ratio [HR]: 4.05; 95% CI: 2.42-6.77) and 1-year mortality (HR: 3.03, 95% CI: 1.98-4.64). The HR for VAN recovery was lower for patients with acute kidney injury (AKI) stage >/=2 (HR: 0.09; 95% CI: 0.02-0.40). Thus, worsening survival outcomes were associated with non-recovery of VAN, whereby AKI stage >/=2 was a significant risk factor. Progression to severe VAN should be prevented for better survival outcomes. |
|---|
| ジャーナル名 | Basic & clinical pharmacology & toxicology |
|---|
| Pubmed追加日 | 2022/9/29 |
|---|
| 投稿者 | Chuma, Masayuki; Hamano, Hirofumi; Bando, Takashi; Kondo, Masateru; Okada, Naoto; Izumi, Yuki; Ishida, Shunsuke; Yoshioka, Toshihiko; Asada, Mizuho; Niimura, Takahiro; Zamami, Yoshito; Takechi, Kenshi; Goda, Mitsuhiro; Miyata, Koji; Yagi, Kenta; Kasamo, Sachiko; Izawa-Ishizawa, Yuki; Azuma, Momoyo; Yanagawa, Hiroaki; Tasaki, Yoshikazu; Ishizawa, Keisuke |
|---|
| 組織名 | Clinical Research Center for Developmental Therapeutics, Tokushima University;Hospital, Tokushima, Japan.;Department of Hospital Pharmacy and Pharmacology, Asahikawa Medical University,;Asahikawa, Japan.;Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan.;Department of Pharmacy, Okayama University Hospital, Okayama, Japan.;Department of Pharmacy, Medical Hospital, Tokyo Medical and Dental University,;Tokyo, Japan.;Department of Clinical Pharmacology and Therapeutics, Tokushima University;Graduate School of Biomedical Sciences, Tokushima, Japan.;Department of Drug Information Analysis, College of Pharmaceutical Sciences,;Matsuyama, Ehime, Japan.;Institutional Research Office, Asahikawa Medical University, Asahikawa, Japan.;Department of Pharmacology, Graduate School of Biomedical Sciences, Tokushima;University, Tokushima, Japan.;Department of Infection Control and Prevention, Tokushima University Hospital,;Tokushima, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/36169161/ |
|---|
